Press Release
Press Release
Press Contacts: Matt Hyams, Erik Cummins, Taina Rosa & Olivia Meyer
11.17.26
Pillsbury advised HealthQuest Capital, a growth equity firm focused on commercial-stage healthcare companies, as lead investor in Galvanize Therapeutics’ oversubscribed $130 million Series D funding round. Galvanize is a commercial-stage company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease.
New investors Olympus Innovation Ventures and Braidwell LP participated in the round alongside existing investors Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates, Inc.
The funding will support the continued commercial expansion of Galvanize’s Aliya® PEF technology, the generation of clinical evidence, the advancement of its RheOx® therapy for chronic bronchitis and the development of next-generation PEF products and platforms.
To learn more, click here.
The Pillsbury deal team was led by Corporate partner Patrick Devine and included partners Richard Blaylock and Jenny Sheng, special counsels Caitlin Stulberg and Olivia Seraphim, and associate Carissa Lee; Intellectual Property partner Jeff Sheriff; Executive Compensation & Benefits partner Jessica Lutrin; Employment Law partner Rebecca Carr Rizzo; Regulatory partner Shruti Bhutani Arora and associate Nathan Banks; and International Trade associate Ethan Cao.